ASH 2020 Updates: Improving Outcomes in TIE-NDMM

December 23, 2020
Targeted Oncology

Implications for assessing MRD status in patients with transplant-ineligible myeloma and treating appropriate patients with the combination of daratumumab, lenalidomide, and dexamethasone.